The PREVENT investigators have reported positive results for the IL-17A inhibitor secukinumab in patients with nonradiographic axial spondyloarthritis at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.
Findings from the DISCOVER-1 and DISCOVER-2 trials suggest that the interleukin-23 inhibitor guselkumab may be a promising treatment option for people with psoriatic arthritis.
Study findings pitting methotrexate plus glucocorticoid treatment against methotrexate plus one of three biologics in early rheumatoid arthritis provide support for the active conventional treatment.
To improve the quality of life of patients with ankylosing spondylitis, research suggests that fatigue, poor sleep, and mental health need to be addressed in addition to managing disease activity and function.
US researchers have identified a number of chronic conditions associated with rheumatoid arthritis, including some that may predispose to RA development and others that may arise as a result of RA.
A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.
Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.
Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
Irene van der Horst Bruinsma discusses the dual benefits of certolizumab pegol for patients with axial spondyloarthritis and a history of acute anterior uveitis (3:32).
